CYP2D6 GA (IM) polymorphism was uncommon among patients, compared with the control group, possibly indicating a protective role of the polymorphisms from Ph-ve CML. This evidence concerns the gene CYP2D6 and chronic myelogenous leukemia, BCR-ABL1 positive.